- Research semaglutide is no longer available from verified suppliers (delisted at CertaPeptides since mid-2026, out of stock at AuraVia Research, never listed at SwissChems or AminoClub): no verified purchase option remains
- Semaglutide is a GLP-1 receptor agonist studied for weight management and metabolism
- Available, verified GLP-1 alternative: retatrutide (triple GIP/GLP-1/glucagon agonist) at AuraVia Research in Europe, as a vial (10 mg at EUR99) or a pre-filled pen (15 mg at EUR199.99), CoA for every batch
- Strictly for research purposes only — not for human consumption
Our Recommendation
Research semaglutide is no longer offered by verified suppliers. After its delisting mid-2026 at CertaPeptides, no verified supplier (CertaPeptides, SwissChems, AminoClub) offers it (AuraVia Research lists it, but it is out of stock). There is therefore no verified purchase option for research semaglutide.
The only GLP-1 peptide still available at our verified European supplier is retatrutide, a triple agonist of the GIP / GLP-1 / glucagon receptors. We present it as the available, verified GLP-1 research alternative.
| Region | Supplier | Available GLP-1 Product | Price | Shipping | Action |
|---|---|---|---|---|---|
| EU Europe (incl. UK, CH, NO) | AuraVia Research | Retatrutide 10 mg (vial) or pre-filled pen | vial from EUR99, pen from EUR199.99 | 3-5 business days (EU) | Order Retatrutide |
| Alternative (EU, UK, CH) | CertaPeptides | Retatrutide | see site | 3-7 days | View at CertaPeptides |
| Semaglutide | Delisted — no longer offered by any verified supplier since mid-2026 | ||||
Important: Retatrutide is a compound strictly for research, not intended for human consumption. Pharmaceutical versions of semaglutide (Ozempic, Wegovy, Rybelsus) are available by prescription only.
AuraVia Research: Retatrutide, the Verified GLP-1 Alternative
AuraVia Research is a European research-peptide supplier that ships from a warehouse in the EU. Semaglutide appears in its catalog, but it is out of stock. The GLP-1 peptide available at this verified supplier is retatrutide, a triple agonist of the GIP / GLP-1 / glucagon receptors, offered as a lyophilized vial and as a pre-filled pen.
Strengths
- EU warehouse: ships across Europe, including the UK, Switzerland and Norway; standard tracked shipping in 3-5 business days within the EU
- Shipping cost: EUR9, free from EUR150 (EU addresses; for the UK, Switzerland and Norway, the cost is shown at checkout)
- Prices in EUR: VAT included
- HPLC purity ≥99%: certificate of analysis (CoA) for every batch
- Two formats: lyophilized vial or ready-to-use pre-filled pen, no reconstitution
Considerations
- Outside the EU (UK, Switzerland, Norway), customs or import duties may apply
- Semaglutide and tirzepatide are listed, but out of stock
Available Retatrutide
| Product | Dosage | Price | Link |
|---|---|---|---|
| Retatrutide (lyophilized vial) | 10 mg / 20 mg | EUR99 / EUR159 | Order Retatrutide |
| Retatrutide (pre-filled pen) | 15 mg / 40 mg | EUR199.99 / EUR349.99 | View the Pre-filled Pen |
The pre-filled pen is ready to use and needs no reconstitution. Our retatrutide pen article covers it in detail, and our vial or pre-filled pen guide compares the two formats. Retatrutide is a compound strictly for research, not intended for human consumption.
Alternative: CertaPeptides (EU, UK, Switzerland)
CertaPeptides, a supplier based in Romania, also offers retatrutide and ships to the EU, the UK and Switzerland: it is a European alternative to AuraVia Research. Shipping in 3-7 business days, 98%+ purity with HPLC and MS testing for each batch, independent CoA (Janoshik / Finnrick), credit card and crypto accepted, returns limited to 14 days. For other GLP-1/incretin compounds, browse its GLP-1 category.
Verified GLP-1 alternative for Europe: AuraVia Research offers retatrutide as a vial and as a pre-filled pen, with a CoA for every batch and shipping from the EU.
View Retatrutide at AuraVia ResearchSemaglutide: Fully Delisted at Verified Suppliers
Since mid-2026, research semaglutide has been fully delisted at verified suppliers. CertaPeptides removed it from its catalog (its former product URLs now redirect to the category page), AuraVia Research lists it but it is out of stock, and neither SwissChems nor AminoClub ever listed it. No verified purchase option remains.
Why the Delisting?
- Likely regulatory withdrawal: Semaglutide is a molecule commercialized in pharmaceutical form (Novo Nordisk: Ozempic, Wegovy, Rybelsus), which exposes its research version to increased scrutiny
- Complex molecule: A 31 amino acid peptide with a specific lipid modification, expensive to synthesize
- High demand: The popularity of Ozempic/Wegovy treatments has created regulatory pressure
Availability at Verified Suppliers
| Supplier | Semaglutide | Available GLP-1 Alternative |
|---|---|---|
| AuraVia Research (Europe incl. UK, CH, NO) | Listed, out of stock | Retatrutide (vial and pre-filled pen) |
| CertaPeptides (EU, UK, Switzerland) | Delisted (mid-2026) | Retatrutide (triple GIP/GLP-1/glucagon agonist) |
| SwissChems | Not available | Not available |
| AminoClub | Not available | Not available |
The only GLP-1 peptide still available at a verified supplier is retatrutide, offered in Europe by AuraVia Research (CertaPeptides remains a European alternative).
GLP-1 alternative for Europe: retatrutide at AuraVia Research (vial from EUR99), also as a pre-filled pen, CoA for every batch.
About Semaglutide
Semaglutide is a synthetic peptide in the class of GLP-1 receptor agonists (glucagon-like peptide-1). It is the subject of intensive research in several fields:
Research Areas
- Weight management: STEP clinical trials showed significant results in obesity research
- Glucose metabolism: Study of mechanism of action on glucose-dependent insulin secretion
- Cardiovascular health: SELECT trial studied effects on cardiovascular events
- Neuroprotection: Emerging research on potential effects on the central nervous system
Molecular Characteristics
| Property | Value |
|---|---|
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113.58 g/mol |
| Half-life | ~7 days (prolonged by albumin binding) |
| Type | GLP-1 receptor agonist |
For more information on mechanism of action and clinical studies, see our complete semaglutide guide.
How to Verify Quality
Since semaglutide is a complex and expensive molecule, it is essential to verify supplier quality:
1. Certificate of Analysis (CoA)
A serious supplier provides a batch-specific CoA. This document should include:
- HPLC chromatogram showing purity (98%+ minimum)
- Mass spectrometry (MS) confirming exact molecular weight (4113.58 g/mol)
- Endotoxin testing
- Batch number matching the label
2. Storage and Shipping
Semaglutide is temperature sensitive:
- Optimal storage at -20C
- Shipping with ice packs or dry ice
- Insulated packaging required
3. Reference Pricing
Quality research semaglutide costs between EUR25 and EUR60 for 5mg. A significantly lower price is a warning sign.
4. Red Flags to Avoid
- No CoA available
- Abnormally low prices (
- Sellers without verifiable history
- Sites without clear legal information
Verified GLP-1 alternative (semaglutide is no longer listed):
- EU Europe (incl. UK, CH, NO): Retatrutide at AuraVia Research (vial or pre-filled pen), CoA for every batch
- Alternative (EU, UK, CH): CertaPeptides
Semaglutide Buying FAQ
Frequently Asked Questions
Is it legal to buy semaglutide for research?
Why is semaglutide so hard to find?
What is the difference between research semaglutide and Ozempic/Wegovy?
How should I store semaglutide after receiving it?
Can I buy semaglutide in the USA?
Where to buy semaglutide in Europe?
Is there a CertaPeptides discount code?
Does AuraVia Research have a discount code?
Recommended products
Research peptides selected for quality and purity:
Retatrutide Pen
Pre-filled Pen Retatrutide
Transform DUO
2-pen pack: Retatrutide, Glow
Retatrutide
Metabolic Peptide
Test your knowledge
Quick quiz · 6 questions
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med, 384(11), 989-1002. (PubMed)
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med, 389(24), 2221-2232. (PubMed)
- Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). N Engl J Med, 375(19), 1834-1844. (PubMed)